Join to view full profile
UTHealth Neurosciences- Texas Medical Center6400 Fannin St. Ste 2800, Dept Of NeurosurgeryHouston, TX 77030
Phone+1 713-486-8000
Fax+1 713-795-8104
Dr. Zhu is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jay-Jiguang Zhu is a neurologist with a subspecialty in Neurooncology, based in Houston, TX. He completed his fellowship in Neuro-Oncology at Massachusetts General Hospital and his residency in Neurology at Tufts Medical Center. Dr. Zhu has been working as the Directory of Neuro-Oncology at the University of Texas Health Science Center in Houston since 2010 and an attending physician and associate professor at Memorial Hermann - Texas Medical Center. His experience includes neuro-oncology, gliomas, and pediatric neuro-oncology. He also has several publications in prestigious medical journals and has led multiple clinical trials primarily focusing on glioblastoma and the reduction of post-lumbar puncture headaches.
Education & Training
Massachusetts General HospitalFellowship, Neuro-Oncology, 2003 - 2005
Tufts Medical CenterResidency, Neurology, 2000 - 2003
Berkshire Medical CenterInternship, Internal Medicine, 1999 - 2000
McGill University Faculty of MedicineClass of 1999
Certifications & Licensure
TX State Medical License 2010 - 2027
MA State Medical License 2005 - 2012
American Board of Psychiatry and Neurology Neurology
United Council for Neurologic SubspecialtiesNeuro-oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification FirstNet (Clinical), Cerner Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification HealthSentry, Cerner Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification FirstNet (Image Results), Cerner Corporation, 2013-2017
Clinical Trials
Publications & Presentations
PubMed
- 1 citationsMolecular Features of Glioblastoma Isocitrate Dehydrogenase-Wildtype in Extreme Survival Groups After Supramaximal and Maximal Resection.Angel Bueno, Antonio Dono, Christian Amezquita-Contreras, Kamand Khalaj, Ankush Chandra
Neurosurgery. 2026-10-01 - The Cortico-Cortical and Subcortical Circuits of the Human Brain Language Centers Including the Dual Limbic and Language Functioning Fiber Tracts.Arash Kamali, Nithya P Narayana, Anastasia Loiko, Anusha Gandhi, Paul E Schulz
Brain Sciences. 2026-01-28 - Glioblastoma IDH-wild type: imaging independent predictors of gross total resection (GTR) using the VASARI feature set and tumoral volumetric measurements.David Timaran-Montenegro, Luis Nunez, Antonio Dono, Octavio Arevalo, Andres Rodriguez
Acta Radiologica. 2025-05-01
Press Mentions
Cancer-Killing Virus plus Immunotherapy Boosts Survival in Aggressive Brain CancerMay 19th, 2023- 'He's My Miracle': Houston Man with Brain Tumor Given Two Months to Live, but He's Still Alive Six Years LaterJuly 18th, 2022
- Asandeutertinib Tops Osimertinib for EGFR + NSCLC with Brain MetastasesJune 2nd, 2026
Professional Memberships
- Member
- Member
- Society of Neuro-oncologyMember
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
